Information Provided By:
Fly News Breaks for March 15, 2016
SNY, MNKD
Mar 15, 2016 | 05:53 EDT
Piper Jaffray analyst Joshua Schimmer attributes MannKind's (MNKD) greater than expected Q4 loss to non-cash impairment charges related to the termination of its commercial agreement with Sanofi (SNY) for Afrezza. The company has a "very short window within which to sufficiently inflect the launch" given its limited financial resources, Schimmer tells investors in a post-earnings research note. He reiterates an Underweight rating on MannKind shares with a 5c price target.
News For MNKD;SNY From the Last 2 Days
SNY
Mar 27, 2024 | 06:16 EDT
Wells Fargo analyst Derek Archila raised the firm's price target on Annexon (ANNX) to $12 from $11 and keeps an Overweight rating on the shares. The firm believes the risk/reward remains favorable ahead of ANX005's Phase 3 data in GBS. Additionally, updates for ANX007 at ARVO, Phase 3 GBS data at PNS and read through from Sanofi's (SNY's) riliprubart in CIDP at AAN, all could offer upside for shares, Wells adds.